These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

965 related articles for article (PubMed ID: 23149331)

  • 21. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
    Jovin IS; Shah RM; Patel DB; Rao SV; Baklanov DV; Moussa I; Kennedy KF; Secemsky EA; Yeh RW; Kontos MC; Vetrovec GW
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1102-1111. PubMed ID: 28527778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
    Feldman DN; Wong SC; Bergman G; Minutello RM
    J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Karayannis G; Angelidis C; Stavrou K; Vavuranakis M; Goudevenos JA; Stefanadis C;
    Cardiovasc Ther; 2014 Jun; 32(3):120-6. PubMed ID: 24512682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial.
    Sanborn TA; Tomey MI; Mehran R; Généreux P; Witzenbichler B; Brener SJ; Kirtane AJ; McAndrew TC; Kornowski R; Dudek D; Nikolsky E; Stone GW
    Catheter Cardiovasc Interv; 2015 Feb; 85(3):371-9. PubMed ID: 25179260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
    Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.
    Shah A; Feldman DN
    Vasc Health Risk Manag; 2012; 8():115-23. PubMed ID: 22399856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis.
    Huang FY; Huang BT; Peng Y; Liu W; Zhao ZG; Wang PJ; Zuo ZL; Zhang C; Liao YB; Luo XL; Meng QT; Chen C; Huang KS; Chai H; Li Q; Chen M; Zhu Y
    Angiology; 2015 Oct; 66(9):845-55. PubMed ID: 25635117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
    Deshpande NV; Pratiti R; Admane P; Mukherjee D; Mardikar HM
    Indian Heart J; 2012; 64(5):444-8. PubMed ID: 23102380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.
    Fabris E; Kilic S; Van't Hof AWJ; Ten Berg J; Ayesta A; Zeymer U; Hamon M; Soulat L; Bernstein D; Anthopoulos P; Deliargyris EN; Steg PG
    JAMA Cardiol; 2017 Jul; 2(7):791-796. PubMed ID: 28273285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
    Liang Z; Li Y; Wang J; Wang D; Wang S; Ma L; Liu H; Yang L; Stone GW; Han Y
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():608-15. PubMed ID: 26762481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bivalirudin for patients with acute coronary syndromes.
    Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
    N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
    Abtahian F; Waldo S; Jang IK
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):390-6. PubMed ID: 25753749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
    Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
    Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial.
    Zeymer U; van 't Hof A; Adgey J; Nibbe L; Clemmensen P; Cavallini C; ten Berg J; Coste P; Huber K; Deliargyris EN; Day J; Bernstein D; Goldstein P; Hamm C; Steg PG
    Eur Heart J; 2014 Sep; 35(36):2460-7. PubMed ID: 24849104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.
    Sardi GL; Lindsay J; Waksman R
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):614-20. PubMed ID: 22581418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
    J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.